

1. Abbott, R. D., Wilson, P. W. F., Kannel, W. B., et al., "High Density Lipoprotein Cholesterol, Total Cholesterol Screening, and Myocardial Infarction: The Framingham Study," Arteriosclerosis 8:207-211, 1988.
2. Abell, L. L., Levy, B. B., Brodie, B. B., et al., "A Simplified Method for the Estimation of Total Cholesterol in Serum and Demonstration of Its Specificity," J. Biol.Chem. 195:357-366, 1952.
3. Adolfsson, R., Svardsudd, K., and Tibblin, G., "1913 Men Study," Scan. J. Soc. Med. 14(suppl.):122-127, 1977.
4. Agner, E., "Some Cardiovascular Risk Factors Are Also Important in Old Age," Acta. Med. Scand. 696, 1985.
5. Agner, E., and Hansen, P. F., "Fasting Serum Cholesterol and Triglycerides in a Ten-Year Prospective Study in Old Age," Acta. Med. Scand. 214:33-41, 1983.
6. American Heart Association, "Public Screening Strategies for Measuring Blood Cholesterol in Adults--Issues for Special Concern," October 1987.
7. Anderson, J. W., "Dietary Fiber, Lipids and Atherosclerosis," Am. J. Cardiol. 60: 17 G-22G, 1987.
8. Anderson, K. M., Castelli, W. P., and Levy, D., "Cholesterol and Mortality: 30 Years of Follow-Up From the Framingham Study," J. A.M.A. 257:2176-2180, 1987.
9. Anderson, J. W., Story, L., Sieling, B., et al., "Hypocholesterolemic Effects of Oat-Bran or Bean Intake for Hypercholesterolemic Men," Am. J. Clin.Nutr. 40:1146-1155, 1984.
10. Anderson, J. W., Story, L., Sieling, B., et al., "Hypocholesterolemic Effect of High Fibre Diet Rich in Water-Soluble Plant Fibres," J. Can. Diet. Assoc. 45:2-5, 1984.
11. Balodimos, M. C., Kealey, O. J., and Hurxthal, L. M., "Serum Cholesterol Values and Vascular Disease," Geriatrics 23: 108-114, 1968.
12. Barrett-Connor, E., and Khaw, K-T., "Borderline Fasting Hypertriglyceridemia: Absence of Excess Risk of All-Cause and Cardiovascular Disease Mortality in Healthy Men Without hypercholesterolemia," Prev. Med. 16:1-8, 1987.
13. Barrett-Connor, E., Suarez, L., Khaw, K-T., et al., "Ischemic Heart Disease Risk Factors After Age 50," J. Chron. Dis. 37:903-908, 1984.
14. Berry, J. E., Uzawa, H., and Fujimi, S., "Stroke U.S. and Japan: Serum Lipid Profiles," Geriatrics 24:126-140, 1969.
15. Berwick, D. M., Cretin, S., and Keeler, E., Cholesterol. Children. and Heart Disease: An Analysis of Alternatives (New York, NY: Oxford University Press, 1980).

16. Blankenhorn, D. H., Nessim, S. A., Johnson, R. L., et al., "Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts," J. A.M.A. 257:3233-3240, 1987.
17. Brown, M. S., and Goldstein, J. L., "Drugs Used in Treatment of Hyperlipidemia," in The Pharmacologic Basis of Therapeutics, A.S. Gilman, L.S. Goodman, T.W. Rail, and F. Murad (eds.) (New York, NY: MacMillan, 1985).
18. Burke, J. J., and Fischer, P. M., "A Clinician's Guide to the Office Measurement of Cholesterol," J. A.M.A. 259:3444-3448, 1988.
19. Bush, T., Johns Hopkins University, School of Public Health and Hygiene, personal communication, August 1988.
20. Canadian Task Force on the Periodic Health Examination, "The Periodic Health Examination," Canadian Medical Association Journal 121:1 194-1254, 1979; and 130:1278-1285, 1980.
21. Canner, P. L., Berge, K. G., Wenger, N. K., et al., "Fifteen Year Mortality in Coronary Drug Project Patients: Long-Term Benefit With Niacin," J. Am. Coll. Cardiol. 8: 1245-1255, 1986.
22. Carlson, L. A., and Bottiger, L. E., "Ischaemic Heart-Disease in Relation to Fasting Values of Plasma Triglycerides and Cholesterol: Stockholm Prospective Study," Lancet 2:865-868, 1972.
23. College of American Pathologists, Comprehensive Chemistry 1987 Survey (Skokie, IL: College of American Pathologists, 1987).
24. Committee of Principal Investigators, "A Cooperative Trial in the Primary Prevention of Ischaemic Heart Disease Using Clofibrate: Report From the Committee of Principal Investigators," Brit. Heart. J. 40:1069-11 18, 1978.
25. Committee of Principal Investigators, "WHO Cooperative Trial on Primary Prevention of Ischaemic Heart Disease With Clofibrate To Lower Serum Cholesterol: Final Mortality Follow-up," Lancet 2:600-604, 1984.
26. Coronary Drug Project Research Group, "Clofibrate and Niacin in Coronary Heart Disease," J. A.M.A. 231:360-381, 1975.
27. Cox D. R., and Oakes D., Analysis of Survival Data (New York, NY: Chapman and Hill, 1984).
28. Coy, J. A., Fanta, C. M., Finkel, A. J., et al., Physician's Current Procedural Terminology (Chicago, IL: The American Medical Association, 1988).
29. Davis, C. E., Gordon, D., LaRosa, J., et al., "Correlations of Plasma High-Density Lipoprotein Cholesterol Levels With Other Plasma Lipid and Lipoprotein Concentrations: The Lipid Research Clinics Program Prevalence Study," Circulation 62(suppl. IV): IV-24 - IV-30, 1980.

30. Dayton, S., Pearce, M. L., Hashimoto, S., et al., "A Controlled Clinical Trial of a Diet High in Unsaturated Fat in Preventing Complications of Atherosclerosis," Circulation 40(suppl.II):II-1 - II-63, 1969.
31. Duncan, I. W., Mather, A., and Cooper, G. R., "The Procedure for the Proposed Cholesterol Reference Method," (Atlanta, GA: Centers for Disease Control, 1982).
32. Dolecek, T. A., Milas, N. C., Van Horn, L. V., et al., "A Long-Term Nutrition Intervention Experience: Lipid Responses and Dietary Adherence Patterns in the Multiple Risk Factor Intervention Trial," J. Am. Diet. Assoc. 86(6):752-758, 1986.
33. Farchi, G., Menotti, A., and Conti, S., "Coronary Risk Factors and Survival Probability From Coronary and Other Causes of Death," Am. J. Epidemiol. 126:400-408, 1987.
34. Feinleib, M., "Summary of a Workshop on Cholesterol and Noncardiovascular Disease Mortality," Prev. Med. 11:360-367, 1982.
35. Fogelholm, R., and Aho, K., "Ischaemic and Cerebrovascular Disease in Young Adults: 2, Serum Cholesterol and Triglyceride Values," Acta. Neurol.Scand. 49:428-433, 1973.
36. Frick, M. H., Elo, O., Haapa, K., et al., "Helsinki Heart Study: Primary-Prevention Trial With Gemfibrozil in Middle-Aged Men With Dyslipidemia," N. Engl. J. Med. 3 17: 1237-1245, 1987.
37. Friedewald, W. T., Levy, R. I., and Fredrickson, D. S., "Estimation of Plasma Low Density Lipoprotein Cholesterol Concentration Without Use of the Preparative Ultracentrifuge," Clin. Chem. 18:499-509, 1972.
38. Fukuzawa, D., Foer's Pharmacy, Washington, DC, personal communication, Dec. 5, 1988.
39. Garber, A. M., Littenberg, B., and Sex, H. C., "Screening Asymptomatic Adults for Cardiac Risk Factors: The Serum Cholesterol Level," accepted for publication in Ann. Intern. Med.
40. Gluck, M. E., Wagner, J. L., and Duffy, B. M., "The Use of Preventive Services by the Elderly," (Washington, DC: Office of Technology Assessment, U.S. Congress, 1989).
41. Goldbourt, U., Holtzman, E., and Neufeld, H. N., "Total and High Density Lipoprotein Cholesterol in the Serum and Risk of Mortality: Evidence of a Threshold Effect," Brit Med. J. 290:1239-1243, 1985.
42. Gordon, D. J., Trost, D. C., Hyde, J., et al., "Seasonal Cholesterol Cycles: The Lipid Research Clinics Coronary Primary Prevention Trial Placebo Group," Circulation 76: 1224-1231, 1987.
43. Gordon, T., Castelli, W. P., and Hjortland, M. C., "High Density Lipoprotein as a Protective Factor Against Coronary Heart Disease: The Framingham Study," Am. J. Med. 62:707-714, 1977.
44. Gordon, T., Castelli, W. P., Hjortland, M. C., et al., "Predicting Coronary Heart Disease in Middle-Aged and Older Persons: The Framingham Study," J. A.M.A. 238:497-499, 1977.

45. Gordon, T., and **Kannel**, W. B., "Predisposition to Atherosclerosis in the Head, Heart, and Legs," J.A.M.A. 221:661-666, 1972.
46. **Gorlin**, R., "The Biological Actions and Potential Clinical Significance of Dietary Omega-3 Fatty Acids," Arch. Intern. Med. 148(9):2043-2048, 1988.
47. Greenland, P., Levenkron, J. C., **Radley**, M. G., et al., "Feasibility of Large-Scale Cholesterol Screening: Experience With a Portable Capillary-Blood Testing Device," Am. J. Pub. Health 77:73-75, 1987.
48. **Grundey**, S. M., "Cholesterol and Coronary Heart Disease," J. A.M.A. 256:2849-2858, 1986.
49. **Grundey**, S. M., Greenland, P., Herd, A., et al., "Cardiovascular and Risk Factor Evaluation of Healthy American Adults," Circulation 75(6) :1340 A-1362A, 1987.
50. **Grundey**, S. M., Vega, G. L., and Bilheimer, D. W., "Influence of Combined Therapy With **Mevinolin** and Interruption of Bile-Acid Reabsorption on Low Density Lipoproteins in Heterozygous Familial hypercholesterolemia," Ann. Intern. Med. 103:339-343, 1985.
51. Harris, T., Cook, E., **Kannel**, W. B., et al., "Proportional Hazards Analysis of Risk Factors for Coronary Heart Disease in Individuals Aged 65 or Older," J. A.G.S. 36: 1023-1028, 1988.
52. Harris, W. S., Connor, W. E., and McMurray, M. P., "The Comparative Reduction of the Plasma Lipids and Lipoproteins by Dietary Polyunsaturated Fats: Salmon Oil Versus Vegetable Oils," Metabolism 32:179-184, 1983.
53. Harris, W. S., **Dujovne**, C. A., **Zucker**, M., et al., "Effects of a Low Saturated Fat, Low Cholesterol Fish Oil Supplement in Hypertriglyceridemic Patients: A Placebo-Controlled Trial," Ann. Intern. Med. 109(6):465-470, 1988.
54. **Havel**, R. J., "High-Density Lipoproteins, Cholesterol Transport and CHD," Circulation 60:1-3, 1979.
55. Hegsted, D. M., and **Nicolosi**, R. J., "Individual Variation in Serum Cholesterol Levels," Proc. Nat. Acad. Sci. 84:6259-6261, 1987.
56. Hjermann, I., Byre, K. V., **Holme**, I., et al., "Effect of Diet and Smoking Intervention on the Incidence of Coronary Heart Disease: Report From the Oslo Study Group of a Randomized Trial in Healthy Men," Lancet 2:1303-1310, 1981.
57. **Holme**, I., Hjermann, I., **Helegeland**, A., et al., "The Oslo Study: Diet and Antismoking Advice. Additional Results From a 5-Year Primary Preventive Trial in Middle-Aged Men," Prev. Med. 14:279-292, 1985.
58. **Hulley**, S. B., and Lo, B., "Choice and Use of Blood Lipid Tests: An Epidemiologic Perspective," Arch. Intern. Med. 143:667-673, 1983.

59. **Hulley, S. B., Rosenman, R. H., Bawol, R. D., et al.**, "Epidemiology as a Guide to Clinical Decisions: The Association Between Triglyceride and Coronary Heart Disease," N. Engl. J. Med 302:1383-1389, 1980.
60. **Iozzia, D.**, Drug Reimbursement Analyst, Blue Cross/Blue Shield of New Jersey, personal communication, Newark, NJ, Feb. 10, 1989.
61. **Kane, J. P., Malloy, M. J., Tun, P., et al.**, "Normalization of Low-Density-Lipoprotein Levels in Heterozygous Familial hypercholesterolemia With a Combined Drug Regimen," N. Engl. J. Med. 304:251-8, 1981.
62. **Kannel, W. B.**, "High-Density Lipoproteins: Epidemiologic Profile and Risks of Coronary Artery Disease," Am. J. Cardiol. 52:9B-12B, 1983.
63. **Kannel, W. B., Castelli, W. P., and Gordon, T.**, "Serum Cholesterol, Lipoproteins, and Risk of Coronary Heart Disease: The Framingham Study," Ann. Intern. Med. 74:1- 12, 1971.
64. **Kannel, W. B., Castelli, W. P., and Gordon, T.**, "Cholesterol in the Prediction of Atherosclerotic Disease: New Perspectives Based on the Framingham Study," Ann. Intern. Med. 90:85-91, 1979.
65. **Kannel, W. B., Gordon, T., and Dawber, T. R.**, "Role of Lipids in the Development of Brain Infarction," Stroke 5:679-685, 1974.
66. **Keys, A.**, Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease (Cambridge, MA: Harvard University Press, 1980).
67. **Kirby, R. W., Anderson, J. W., and Sieling, B.**, "Oat Bran Intake Selectively Lowers Serum LDL-Cholesterol Concentration," Am. J. Clin. Nutr. 34:824-9, 1981.
68. **Knopp, R. H., Brown, W. V., Dujovne, C. A., et al.**, "Effect of Fenofibrate on Plasma Lipoproteins in hypercholesterolemia and Combined Hyperlipidemia," Am. J. Med. 83(suppl. 5B):50-59, 1987.
69. **Koch, D. D., Hassemer, D. J., Wiebe, D. A., et al.**, "Testing Cholesterol Accuracy," J. A.M.A. 260:2552-2557, 1988.
70. **Kroll, M. H., Lindsey, H., Greene, J., et al.**, "Bias Between Enzymatic Methods and the Reference Method for Cholesterol," Clinical Chemistry 34:131 -135, 1988.
71. **Kronmal, R. A.**, "Commentary on the Published Results of the Lipid Research Clinics Coronary Primary Prevention Trial," J. A.M.A. 253:2091 -2093, 1985.
72. **Kuske, T. T., and Feldman, E. B.**, "Hyperlipoproteinemia, Atherosclerosis Risk, and Dietary Management," Arch. Intern. Med. 147:357-360, 1987.
73. **Ladenson, J. H.**, "Cholesterol," Gradwohl's Clinical Laboratory Methods and Diagnosis, A.C. Sonnenwirth and L. Jarett(eds.) (St. Louis, MO: C.V. Mosby Co., 1980).

74. **Lardinois, C. K., and Neuman, S. L.,** "The Effects of Antihypertensive Agents on Serum Lipids and Lipoproteins," Arch. Intern. Med. 148:1280-1288, 1988.
75. **LaRosa, J. C., Chambless, L. E., Criqui, M. H., et al.,** "Patterns of Dyslipoproteinemia in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study," Circulation 73(Suppl. I):I-12 - I-29, 1986.
76. **Levy, R. I., Brensike, J. F., Epstein, S. E., et al.,** "The Influence of Changes in Lipid Values Induced by **Cholestyramine** and Diet on Progression of Coronary Artery Disease: Results of the NHLBI Type 11 Coronary Intervention Study," Circulation 69:325-337, 1984.
77. **Levy, R. I., Fredrickson, D. S., Shulman, R., et al.,** "Cholestyramine in Type II Hyperlipoproteinemia: A Double-Blind Trial," Ann. Intern. Med. 79:51-58, 1973.
78. **Lipid Research Clinics Program,** "The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease," J. A.M.A. 251:351-364, 1984.
79. **Lipid Research Clinics Program,** "The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The Relation of Reduction in Incidence of Coronary Heart Disease to Cholesterol Lowering," J. A.M.A. 251:365-374, 1984.
80. **Lovastatin Study Group II,** "Therapeutic Response to Lovastatin (Mevinolin) in Non-familial hypercholesterolemia: A Multicenter Study," J. A.M.A. 256:2829-2834, 1986.
81. **Luger, S.,** Chief Pharmaceutical Consultant, Pharmacy Assistance to the Aged and Disabled Program, Trenton, NJ, personal communication, Dec. 5, 1988.
82. **Mabuchi, H., Takeshi, S., Sakai, Y., et al.,** "Reduction of Serum Cholesterol in Heterozygous Patients With Familial hypercholesterolemia: Additive Effects of Compactin and Cholestyramine," N. Engl. J. Med. 308:609-613, 1983.
83. **Malinow, M. R., and Blaton, V.,** "Regression of Atherosclerotic Lesions," Arteriosclerosis 4:292-295, 1984.
84. **Manninen, V., Elo, O., and Frick, H.,** "Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study," J. A.M.A. 260:641-651, 1988.
85. **Martin, M. J., Hulley, S. B., and Browner, W. S.,** "Serum Cholesterol, Blood Pressure, and Mortality: Implications From a Cohort of 361,662 Men," Lancet 2:933-936, 1986.
86. **Menotti, A., and Seccareccia, F.,** "Blood Pressure, Serum Cholesterol and Smoking Habits Predicting Different Manifestations of Arteriosclerotic Cardiovascular Diseases," Acta. Cardiol. (Brux) 42:91-102, 1987.
87. **Mullen, C.,** Health Care Financing Administration, personal communication, Baltimore, MD, July 1988.
88. **Multiple Risk Factor Intervention Trial Research Group,** "Multiple Risk Factor Intervention Trial: Risk Factor Changes and Mortality Results," J. A.M.A. 248: 1465-1477, 1982.

89. Munoz, J. M., Sandstead, J., Jacob, R. A., et al., "Effects of Some Cereal Brans and Textured Vegetable Protein on Plasma Lipids," Am. J. Clin. Nutr. 32:58-62, 1979.
90. Naito, H. K., "Cholesterol," in Clinical Chemistry: Theory, Analysis, and Correlation, L.A. Kaplan and A.J. Pesce (eds.) (St. Louis, MO: C.V. Mosby Co., 1984).
91. Naito, H. K., "How To Ensure Reliable Cholesterol Measurement?" presentation to the First National Cholesterol Conference, Hyatt Crystal City, Alexandria, VA, Nov. 4, 1988.
92. Naito, H. K., "Reliability of Lipid, Lipoprotein, Apolipoprotein Measurements," Clinical Chemistry 34(8 B): B84-B94, 1988.
93. Neaton, J. D., Kuller, L. H., Wentworth, D., et al., "Total and Cardiovascular Mortality in Relation to Cigarette Smoking, Serum Cholesterol Concentration, and Diastolic Blood Pressure Among Black and White Males Followed Up for Five Years," Am. Heart. J. 108:759-769, 1984.
94. Newton, M., Health Care Financing Administration, Baltimore, MD, personal communication, October 1988.
95. Ouslander, J. G., "Drug Therapy in the Elderly," Ann. Intern. Med. 95:711-722, 1981.
96. Power, E. J., Wagner, J. L., and Duffy, B. D., "Screening for Open-Angle Glaucoma in the Elderly," (Washington, DC: U.S. Congress, Office of Technology Assessment, 1988).
97. Reed, D., Yano, K., and Kagan, A., "Lipids and Lipoproteins as Precursors of Coronary Heart Disease, Stroke, and Cancer in the Honolulu Heart Program," Am. J. Med. 80:871 - 878, 1986.
98. Rhoads, G. G., Popper, J. S., Kagan, A., et al., "Incidence of Transient Cerebral Ischemic Attack in Hawaiian Japanese Men," Stroke 11 :21-26, 1980.
99. Rose, G., and Shipley, M., "Plasma Cholesterol Concentration and Death From Coronary Heart Disease: 10 Year Results of the Whitehall Study," Brit. Med. J. 293:306-307, 1986.
100. Rosenhamer, G., and Carlson, L. A., "Effect of Combined Clofibrate-Nicotinic Acid Treatment in Ischemic Heart Disease," Atherosclerosis 37:129-138, 1980.
101. Rowe, J. W., and Besdine, R. W., "Drug Therapy," in Health and Disease in Old Age, J.W. Rowe and R.W. Besdine (eds.) (Boston, MA: Little Brown, 1982).
102. Salonen, J. T., Puska, P., Tuomilehto, J., et al., "Relation of Blood Pressure, Serum Lipids, and Smoking to the Risk of Cerebral Stroke," Stroke 13:327-333, 1982.
103. Schaffarzick, R., Blue Shield of California, personal communication, November 1988.
104. Schatzkin, A., Hoover, R. N., and Taylor, P. R., "Serum Cholesterol and Cancer in the NHANES I Epidemiologic Followup Study," Lancet 2:298-301, 1987.

-
105. **Schucker**, B., Wittes, J. T., Cutler, J. A., et al., "Change in Physician Perspective on Cholesterol and Heart Disease: Results From Two National Surveys," J. A.M.A. 258:3521-3526, 1987.
 106. Sherwin, R. W., Wentworth, D. N., Cutler, J. A., et al., "Serum Cholesterol Levels and Cancer Mortality in 361,662 Men Screened for the Multiple Risk Factor Intervention Trial," J. A.M.A. 257:943-948, 1987.
 107. Sidney, S., and **Farquhar**, J. W., "Cholesterol, Cancer, and Public Policy," Am. J. Med. 75:494-508, 1983.
 108. Stein, E. A., "Lipids, Lipoproteins, and Apolipoproteins," Fundamentals of Clinical Chemistry, 3rd ed., N.W. Tietz (ed.) (Philadelphia, PA: W.B. Saunders Co., 1987).
 109. Tanaka, H., Ueda, Y., Hayashi, M., et al., "Risk Factors for Cerebral Hemorrhage and Cerebral Infarction in a Japanese Rural Community," Stroke 13:62-73, 1982.
 110. Thomas, C. B., **Holljes**, H. W. D., and Eisenberg, F. F., "Observations on Seasonal Variations in Total Serum Cholesterol Level Among Healthy Young Prisoners," Ann. Intern. Med. 54:413-430, 1961.
 111. Ueshima, H., **Iida**, M., Shimamoto, T., et al., "Multivariate Analysis of Risk Factors for Stroke," Prev. Med. 9:722-740, 1980.
 112. U.S. Congress, Office of Technology Assessment, "Staff Memorandum on the Health Effects of Fish Oil," February 1984.
 113. U.S. Department of Commerce, Bureau of the Census, "Projections of the Population of the United States by Age, Sex, and Race, 1983 -2000," Current Population Reports, Population Estimates and Projections Series P-25, No. 952 (Washington, DC: Government Printing Office, 1984).
 114. U.S. Department of Health and Human Services, National Institutes of Health, "Consensus Conference: Lowering Blood Cholesterol To Prevent Heart Disease," J. A.M.A. 253:2080-2090, 1985.
 115. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and **Blood** Institute, "Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death Using Pooled Repeated Biennial Measurements: Framingham Heart Study, 30-Year Followup," The Framingham Study: An Epidemiological investigation of Cardiovascular Disease, **W.B. Kannel, P.A. Wolf, and R.J. Garrison (eds.)**, NIH Publication No. 87-2703 (Springfield, VA: National Technical Information Service, 1987).
 116. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and **Blood** Institute, National Cholesterol Education Program, Adult Treatment Panel, "Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults," Arch. Intern. Med. 148:36-69, 1988.

117. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cholesterol Education Program, Laboratory Standardization Panel, "Current Status of Blood Cholesterol Measurement in Clinical Laboratories in the United States," Clin. Chem. 34:193-201, 1988.
118. U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics, R. Fullwood, W. Kalsbeck, B. Rifkin, et al., "Total Serum Cholesterol Levels of Adults 20-74 Years of Age: United States, 1976 -80," Vital and Health Statistics, Series 2, No. 2, DHHS Pub. No. (PHS) 86-1686 (Washington, DC: U.S. Government Printing Office, May 1986).
119. U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics, unpublished data from the National Health and Nutrition Examination Survey, 1986.
120. U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics, "Current Estimates From the National Health Interview Survey, United States, 1985," Vital and Health Statistics, Series 10, No. 160., DHHS Pub. No. (PHS) 86-1588 (Washington, DC: U.S. Government Printing Office, 1986).
121. U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics, "Health Statistics on Older Persons: United States, 1986," Vital and Health Statistics, Series 3, No. 25, DHHS Pub. No. (PHS) 87-1409 (Washington, DC: U.S. Government Printing Office, June 1987).
122. U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics, "Health, United States 1987," DHHS Pub. No. (PHS) 88-1232 (Washington, DC: U.S. Government Printing Office, March 1988).
123. Vega, G. L., and Grundy, S. M., "Treatment of Primary Moderate hypercholesterolemia With Lovastatin (Mevinolin) and Colestipol," J. A.M.A. 257:33-38, 1987.
124. Von Lossonczy, T. O., Ruiler, A., Bronsqueest-Schoute, H. C., et al., "The Effect of a Fish Diet on Serum Lipids in Healthy Human Subjects," Am. J. Clin. Nutr. 31: 1340-1346, 1987.
125. Von Schacky, C., "Prophylaxis of Atherosclerosis With Marine Omega-3 Fatty Acids," Ann. Intern. Med. 107:890-899, 1987.
126. Welborn, T., and Wearne, K., "Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton With Reference to Glucose and Insulin Concentrations," Diabetes Care 2:154-160, 1979.
127. Westlund, K., and Nicolaysen, R., "Ten-Year Mortality and Morbidity Related to Serum Cholesterol," Scan. J. Clin. Lab. Invest. 127(suppl.):1-24, 1972.
128. Yaari, S., Goldbourt, U., Even-Zohar, S., et al., "Associations of Serum High Density Lipoprotein and Total Cholesterol With Total, Cardiovascular, and Cancer Mortality in a 7-Year Prospective Study of 10,000 Men," Lancet 1: 1011-1015, 1981.